Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Virpax Pharmaceuticals Inc
(NQ:
VRPX
)
0.8135
-0.0020 (-0.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Virpax Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
12 Health Care Stocks Moving In Monday's After-Market Session
September 11, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 05, 2023
Via
Benzinga
Virpax Pharmaceuticals Updates on Litigation
September 05, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 04, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 01, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
August 31, 2023
Via
Benzinga
Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments
August 14, 2023
From
Virpax® Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method
August 10, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 24, 2023
Via
Benzinga
Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023
July 24, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
July 21, 2023
Via
Benzinga
Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery
July 13, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
June 28, 2023
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on!
Via
InvestorPlace
Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council
June 21, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Announces CFO Transition
June 20, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
June 13, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments
May 12, 2023
From
Virpax® Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar
May 10, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023
May 04, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™
April 27, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Reports on Progress of Envelta™
April 05, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors
March 28, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals 2022 R&D Expenses Grow 122% To $10.8M, Here Are The Details
March 22, 2023
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) released its financial results for the twelve months ended December 31, 2022, and other recent developments. FY 2022 Financial Highlights
Via
Benzinga
Virpax Pharmaceuticals Reports 2022 Year-End Results
March 22, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
March 14, 2023
Via
Benzinga
Virpax Completes FDA Required Preclinical Toxicology Studies For Its Licensed Molecular Envelope Technology
February 13, 2023
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX), has completed FDA required preclinical toxicology studies for its licensed Molecular Envelope Technology (MET). MET enhances the delivery of Virpax’s...
Via
Benzinga
Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)
February 13, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
February 02, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.